Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma”

99 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 99 results

Large-scale testing (Phase 3)Looking for participantsNCT07043400
What this trial is testing

Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
BeOne Medicines 351
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Early research (Phase 1)Study completedNCT04805307
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Who this might be right for
Advanced Solid TumorGastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)Pancreatic Cancer
Keymed Biosciences Co.Ltd 176
Testing effectiveness (Phase 2)Study completedNCT00780494
What this trial is testing

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Who this might be right for
Stomach CancerGastric (Stomach) CancerNeoplasm of Cardioesophageal Junction+1 more
Stanford University 35
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Not applicableUnknownNCT04915807
What this trial is testing

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Hallym University Medical Center 222
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)UnknownNCT04263870
What this trial is testing

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more
Sichuan University 36
Testing effectiveness (Phase 2)Study completedNCT03083613
What this trial is testing

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Chinese Academy of Medical Sciences 41
Testing effectiveness (Phase 2)Looking for participantsNCT07102901
What this trial is testing

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 351
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Testing effectiveness (Phase 2)Study completedNCT03196232
What this trial is testing

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal Carcinoma+4 more
George Albert Fisher 3
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Testing effectiveness (Phase 2)Looking for participantsNCT06730373
What this trial is testing

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Who this might be right for
HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
Qilu Hospital of Shandong University 110
Testing effectiveness (Phase 2)Study completedNCT00526110
What this trial is testing

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Who this might be right for
Gastrointestinal Diseases
M.D. Anderson Cancer Center 98
Testing effectiveness (Phase 2)Looking for participantsNCT06251973
What this trial is testing

AgenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Who this might be right for
Metastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Gastric Cancer+10 more
Memorial Sloan Kettering Cancer Center 37
Load More Results
377